📊 RPID Key Takeaways
Is Rapid Micro Biosystems, Inc.. (RPID) a Good Investment?
Rapid Micro Biosystems faces severe fundamental challenges with catastrophic unit economics (4.6% gross margin) and unsustainable cash burn ($15.1M operating outflow annually) against minimal cash reserves of $13.8M, leaving less than one year of runway. Despite 19.7% revenue growth, the company loses $1.78 for every dollar of revenue generated, indicating growth destroying shareholder value rather than building it.
Revenue is growing (+19.7% YoY), but the business remains far from breakeven with operating and net margins around -140% and a -95% FCF margin, pointing to weak unit economics and heavy overhead. Liquidity ratios are solid and leverage is modest, yet $20M in cash versus -$31.9M FCF suggests a short runway and potential need for external financing. Until margins improve and cash burn materially declines, the fundamental risk/reward is unfavorable.
Why Buy Rapid Micro Biosystems, Inc.. Stock? RPID Key Strengths
- Revenue growing 19.7% year-over-year showing market demand
- Adequate short-term liquidity with 2.57x current ratio
- Positive stockholders' equity of $20.4M providing some capital cushion
- Strong liquidity (current 3.31x, quick 2.36x)
- Double-digit revenue growth from a small base
- Modest leverage and low capex intensity
RPID Stock Risks: Rapid Micro Biosystems, Inc.. Investment Risks
- Operating cash burn of $15.1M annually with only $13.8M cash on hand (sub-one-year runway)
- Critically low 4.6% gross margin indicates severe unit economics and pricing power problems
- Cannot service $19.1M debt load from operations with negative interest coverage of -659.6x, creating refinancing risk
- Negative operating margin of -173.1% means business model is fundamentally broken; growth is value-destructive
- Company burns $1.78 for every dollar of revenue, unsustainable without major restructuring or capital infusion
- Persistent, deep operating losses and negative margins
- Heavy cash burn relative to cash on hand, raising financing/dilution risk
- Severely negative ROE/ROA indicating ongoing value destruction
Key Metrics to Watch
- Gross margin trend (must improve to >25% minimum for viability)
- Monthly cash burn rate and remaining runway duration
- Operating cash flow path to positive (critical within 6 months)
- Debt refinancing needs and covenant compliance status
- Operating cash flow and cash balance (runway)
- Gross and operating margin trajectory
Rapid Micro Biosystems, Inc.. (RPID) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.57x current ratio provides a solid financial cushion.
RPID Profit Margin, ROE & Profitability Analysis
RPID vs Industrial Sector: How Rapid Micro Biosystems, Inc.. Compares
How Rapid Micro Biosystems, Inc.. compares to Industrial sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Rapid Micro Biosystems, Inc.. Stock Overvalued? RPID Valuation Analysis 2026
Based on fundamental analysis, Rapid Micro Biosystems, Inc.. shows some fundamental concerns relative to the Industrial sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Rapid Micro Biosystems, Inc.. Balance Sheet: RPID Debt, Cash & Liquidity
RPID Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Rapid Micro Biosystems, Inc..'s revenue has grown significantly by 45% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.08 indicates the company is currently unprofitable.
RPID Revenue Growth, EPS Growth & YoY Performance
RPID Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $7.2M | -$11.3M | $-0.26 |
| Q3 2025 | $7.6M | -$11.3M | $-0.26 |
| Q2 2025 | $6.6M | -$11.3M | $-0.27 |
| Q1 2025 | $5.6M | -$11.3M | $-0.26 |
| Q3 2024 | $6.1M | -$11.3M | $-0.26 |
| Q2 2024 | $5.0M | -$12.6M | $-0.29 |
| Q1 2024 | $5.0M | -$13.3M | $-0.31 |
| Q3 2023 | $4.7M | -$13.1M | $-0.31 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Rapid Micro Biosystems, Inc.. Dividends, Buybacks & Capital Allocation
RPID SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Rapid Micro Biosystems, Inc.. (CIK: 0001380106)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RPID
What is the AI rating for RPID?
Rapid Micro Biosystems, Inc.. (RPID) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RPID's key strengths?
Claude: Revenue growing 19.7% year-over-year showing market demand. Adequate short-term liquidity with 2.57x current ratio. ChatGPT: Strong liquidity (current 3.31x, quick 2.36x). Double-digit revenue growth from a small base.
What are the risks of investing in RPID?
Claude: Operating cash burn of $15.1M annually with only $13.8M cash on hand (sub-one-year runway). Critically low 4.6% gross margin indicates severe unit economics and pricing power problems. ChatGPT: Persistent, deep operating losses and negative margins. Heavy cash burn relative to cash on hand, raising financing/dilution risk.
What is RPID's revenue and growth?
Rapid Micro Biosystems, Inc.. reported revenue of $8.0M.
Does RPID pay dividends?
Rapid Micro Biosystems, Inc.. does not currently pay dividends.
Where can I find RPID SEC filings?
Official SEC filings for Rapid Micro Biosystems, Inc.. (CIK: 0001380106) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RPID's EPS?
Rapid Micro Biosystems, Inc.. has a diluted EPS of $-0.31.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RPID a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Rapid Micro Biosystems, Inc.. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RPID stock overvalued or undervalued?
Valuation metrics for RPID: ROE of -70.0% (sector avg: 15%), net margin of -178.4% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy RPID stock in 2026?
Our dual AI analysis gives Rapid Micro Biosystems, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RPID's free cash flow?
Rapid Micro Biosystems, Inc..'s operating cash flow is $-15.1M, with capital expenditures of $394.0K. FCF margin is -193.1%.
How does RPID compare to other Industrial stocks?
Vs Industrial sector averages: Net margin -178.4% (avg: 10%), ROE -70.0% (avg: 15%), current ratio 2.57 (avg: 1.8).